Prestige BioPharma of Singapore has successful clinical trials to support its bid to market a trastuzumab, based on findings presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.
A trastuzumab biosimilar candidate (HD201, Tuznue) was shown to be highly comparable to reference trastuzumab (Herceptin) in study findings presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.
The biosimilar agent is the lead biosimilar candidate under development at Prestige BioPharma of Singapore, which also has bevacizumab and adalimumab biosimilars in clinical trials, as well as denosumab, aflibercept, eculizumab, and ipilimumab biosimilars in preclinical and discovery stages.
Prestige BioPharma has a regulatory application for Tuznue under review by the European Medicines Agency. The company has contracted with UK-based Mundipharma International to distribute the trastuzumab product in European markets and is seeking approval for all of the same indications as Herceptin. It has also entered into an exclusive agreement with Pharmapark LLC to supply and commercialize the biosimilar in Russia.
Two Clinical Studies
Two clinical similarity trials of Tuznue were undertaken: TROIKA-I and TROIKA. In TROIKA-I, 101 healthy individuals were randomized to either Tuznue or EU or US Herceptin products. They each received a single 6 mg/kg intravenous dose over a 90-minute infusion. The intent was to measure pharmacokinetic (PK) and safety equivalency.
TROIKA-I demonstrated that the biosimilar was safe and well tolerated with PK comparable to Herceptin, investigators said.
The second study, TROIKA, was designed to compare safety, PK, and efficacy, based on the total pathological complete response rate (tpCR). This was a randomized, double-blind, multicenter phase 3 trial. Patients were given Tuznue or EU-Herceptin in combination with chemotherapy in the neoadjuvant setting followed by trastuzumab monotherapy in the adjuvant phase. There were 574 patients evaluable for response.
Investigators said 46.6% of patients in the Tuznue arm achieved tpCR versus 46.2% of patients in the Herceptin arm; 55.0% of patients achieved breast pathological CR in the Tuznue arm versus 53.4% in the Herceptin arm; and the overall response rate was 90.8% versus 89.4%, respectively. These results all demonstrated equivalence between the biosimilar and reference products, investigators said.
Further, PK trough levels met the predefined equivalency margins. The adverse event profile for the biosimilar also demonstrated equivalence in the head-to-head test. The incidence of serious adverse events was 5.6% for Tuznue versus 4.4% for Herceptin.
Investigators said a follow-up study for TROIKA is ongoing, and complete safety, immunogenicity, and survival data are pending.
Reference
Hii J, Pivot X, Mclendon K, et al. Establishing analytical and clinical similarity between HD201 and Herceptin. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020. Abstract 579
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.